Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

Effect of canagliflozin on liver function tests in patients with type 2 diabetes

(2016) L.A. Leiter et al.   DIABETES & METABOLISM

The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome

(2016) Nancy E. Aguilar-Olivos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

(2016) Yasushi Honda et al.   PLoS One

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

(2016) Chikara Komiya et al.   PLoS One

The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial

(2015) Leon A. Adams et al.   HEPATOLOGY

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

(2015) Shirong Qiang et al.   Diabetology & Metabolic Syndrome

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

(2014) Masanori Yokono et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus

(2011) Tomoyuki Iwasaki et al.   HEPATO-GASTROENTEROLOGY

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

(2009) Kittichai Promrat et al.   HEPATOLOGY

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis

(2008) R. LOOMBA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS